236 related articles for article (PubMed ID: 35185926)
21. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
22. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
[TBL] [Abstract][Full Text] [Related]
23. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
24. Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review.
Li L; Wu C; Chai Y; Dong C; Zhao L
Int J Immunopathol Pharmacol; 2021; 35():20587384211009342. PubMed ID: 33845613
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review.
Jin J; Zheng C; Wu S
Medicine (Baltimore); 2018 Jan; 97(2):e9611. PubMed ID: 29480865
[TBL] [Abstract][Full Text] [Related]
26. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
27. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
Liang X; Guo L; Hu X; Li S; Wen S
Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
[TBL] [Abstract][Full Text] [Related]
28. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
29. Chidamide tablets: HDAC inhibition to treat lymphoma.
Xu Y; Zhang P; Liu Y
Drugs Today (Barc); 2017 Mar; 53(3):167-176. PubMed ID: 28447074
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
32. Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma.
Song W; Chen Z; Shi C; Gao Y; Feng X; Li H; Li Z; Zhang M
Hematol Oncol; 2023 Apr; 41(2):257-266. PubMed ID: 34854108
[TBL] [Abstract][Full Text] [Related]
33. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
[TBL] [Abstract][Full Text] [Related]
34. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
[TBL] [Abstract][Full Text] [Related]
35. Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients.
Xu P; Yu D; Wang L; Shen Y; Shen Z; Zhao W
Ann Hematol; 2015 Feb; 94(2):239-47. PubMed ID: 25193354
[TBL] [Abstract][Full Text] [Related]
36. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience.
Rohlfing S; Dietrich S; Witzens-Harig M; Hegenbart U; Schönland S; Luft T; Ho AD; Dreger P
Ann Hematol; 2018 Jul; 97(7):1241-1250. PubMed ID: 29549411
[TBL] [Abstract][Full Text] [Related]
37. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
Savage KJ; Chhanabhai M; Gascoyne RD; Connors JM
Ann Oncol; 2004 Oct; 15(10):1467-75. PubMed ID: 15367405
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
[TBL] [Abstract][Full Text] [Related]
39. Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma.
Gui L; Cao J; Ji D; Zhang H; Fan Q; Zhu J; Song Y; Jiang S; Ning Z; Yu J; Shi Y
Chin J Cancer Res; 2021 Oct; 33(5):616-626. PubMed ID: 34815635
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
Gu R; Liu T; Zhu X; Gan H; Wu Z; Li J; Zheng Y; Dou G; Meng Z
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1000():181-6. PubMed ID: 26245362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
